Plastics reset in an adult Procellariform seabird species during the breeding season.

Plastic ingestion has been extensively studied in seabirds. However, knowledge gaps remain in understanding how plastic loads behave over time and their residence inside Procellariforms. This study investigated the temporal dynamics of ingested plastics by adult Cory's shearwaters (Calonectris borealis) during the breeding season to shed light on plastic retention times.

Late-Life Alcohol Exposure Does Not Exacerbate Age-Dependent Reductions in Mouse Spatial Memory and Brain TFEB Activity.

Alcohol consumption is believed to affect Alzheimer's disease (AD) risk, but the contributing mechanisms are not well understood. A potential mediator of the proposed alcohol-AD connection is autophagy, a degradation pathway that maintains organelle and protein homeostasis. Autophagy is regulated through the activity of Transcription factor EB (TFEB), which promotes lysosome and autophagy-related gene expression.

A Continuous Improvement Instrument for the evaluationof the ergonomics management system in the supply chain.

Nowadays, organizations must comply with high-quality standards, health and safety regulations, and socially sustainable practices to succeed in a globalized world. Supply Chains (SC) enable them to satisfy their customers' needs for quality products just in time and at the best price. However, management systems (MS) need to be improved to identify, evaluate, and control ergonomic risks, which opens a research opportunity for Ergonomics Management Systems (EMS) as they apply to sustainable SCs.

Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene Ciloleucel.

Axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor T-cell therapy, has significantly improved clinical outcomes in adult patients with relapsed/refractory large B-cell lymphoma. However, few studies have examined patient-reported outcomes (PROs) or neurocognitive performance in patients treated with axi-cel. Moreover, no longitudinal PRO study has reported on patients treated with axi-cel as standard of care in the United States, to our knowledge.